| Autor: |
Cuchacovich, M., Ferreira, L., Aliste, M., Soto, L., Cuenca, J., Cruzat, A., Gatica, H., Schiattino, I., Perez, C., Aguirre, A., Salazar-Onfray, F., Aguillón, J. C. |
| Předmět: |
|
| Zdroj: |
Scandinavian Journal of Rheumatology; Aug2004, Vol. 33 Issue 4, p228-232, 5p |
| Abstrakt: |
Objective : To investigate the influence of -308 tumour necrosis factor-α (TNF-α) promoter polymorphism and circulating TNF-α levels in the clinical response to the infliximab treatment in patients with rheumatoid arthritis (RA). Methods : One hundred and thirty-two RA patients were genotyped for TNF-α promoter by polymerase-chain reaction restriction fragment-length polymorphism (PCR-RFLP) analysis. Ten patients with the -308 TNF-α gene promoter genotype G/A, and 10 with the G/G genotype were selected and received 3 mg/kg of infliximab at Weeks 0, 2, 6, and 14. Results : Both groups showed a significant improvement with treatment in all variables studied. Total mean TNF-α levels increased significantly with respect to basal levels in most of patients after treatment [probability (p)=0.04]. Only patients from G/A showed a statistically significant correlation between ACR 50 and the increase of TNF-α levels (p<0.03). Conclusion : A relationship was detected between ACR criteria of improvement and increased circulating TNF-α levels in RA patients subjected to anti-TNF-α therapy. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
